Evaxion Biotech A/SNASDAQ:EVAXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.3700
- TODAY'S CHANGE (%)-0.0300 (-2.1429%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close1.3800 / 1.4000
- Day Range
- 52 Week Range
- Volume26,732
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EVAX |
|---|---|---|
| 09:32 ET | 2774 | 1.4 |
| 09:37 ET | 100 | 1.35 |
| 09:44 ET | 800 | 1.4069 |
| 10:00 ET | 100 | 1.395 |
| 10:02 ET | 953 | 1.41 |
| 10:11 ET | 3954 | 1.35 |
| 10:56 ET | 157 | 1.4 |
| 11:12 ET | 728 | 1.41 |
| 11:16 ET | 238 | 1.41 |
| 11:36 ET | 100 | 1.4 |
| 12:46 ET | 150 | 1.4639 |
| 01:15 ET | 300 | 1.465 |
| 02:00 ET | 119 | 1.441 |
| 02:12 ET | 1000 | 1.4101 |
| 02:21 ET | 7654 | 1.3 |
| 02:41 ET | 900 | 1.37 |
| 02:45 ET | 500 | 1.3749 |
| 03:14 ET | 500 | 1.3434 |
| 03:26 ET | 100 | 1.38 |
| 03:33 ET | 1200 | 1.33 |
| 03:37 ET | 358 | 1.36 |
| 03:53 ET | 265 | 1.374 |
| 03:55 ET | 200 | 1.39 |
| 04:00 ET | 319 | 1.37 |
Nov 18, 2024
*DJ Evaxion Biotech Offering Up to 5.25M ADSs, from 5:15PM ET on Monday Nov 18, 2024 by Dow Jones
5:15PM ET on Monday Nov 18, 2024 by Dow Jones
Nov 13, 2024
Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing, from 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 1, 2024
DJ Evaxion Biotech Price Target Maintained With a $14.00/Share by HC Wainwright & Co., from 6:48AM ET on Friday Nov 01, 2024 by Dow Jones
6:48AM ET on Friday Nov 01, 2024 by Dow Jones
Oct 31, 2024
Press Release: Evaxion announces business update and third quarter 2024 financial results, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Evaxion Biotech A/S | 7.8M | -0.1x | --- |
Mustang Bio Inc | 7.8M | -0.1x | --- |
Galecto Inc | 7.7M | -0.3x | --- |
Virax Biolabs Group Ltd | 7.7M | -0.6x | --- |
Moleculin Biotech Inc | 7.6M | -0.2x | --- |
Cardio Diagnostics Holdings Inc | 7.5M | -0.6x | --- |
Company Information
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Contact Information
- Headquarters
- Bredgade 34E, Copenhagen KCOPENHAGEN, Denmark 1260
- Phone
- ---
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.6M |
|---|---|
Revenue (TTM) | $3.3M |
Shares Outstanding | 557.6K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.35 |
EPS | $-16.80 |
Book Value | $-1.25 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 2.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -457.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
